Tau protein inhibitors - Pipeline Insight, 2024

This “Tau protein inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Tau protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Tau protein inhibitors Understanding

Tau protein inhibitors: Overview

Tau proteins are proteins that perform the function of stabilizing microtubules. These proteins are abundant in nerve cells and are present to a much lesser degree in oligodendrocytes and astrocytes. When Tau proteins become defective and fail to adequately stabilize microtubules, pathologies of the nervous system can develop such as Alzheimer’s disease.

Function - Tau proteins are mainly active in the distal portions of axons where they stabilize microtubules as well as providing flexibility. The proteins work together with a globular protein called tubulin to stabilize microtubules and aid the assembly of tubulin in the microtubules. Tau proteins achieve their control of microtubule stability through isoforms and phosphorylation. Hyperphosphorylation of tau proteins can cause the helical and straight filaments to tangle (referred to as neurofibrillary tangles). These tangles contribute to the pathology of Alzheimer’s disease.

Tau protein inhibitors - Alzheimer disease is characterized by pathological aggregation of two proteins, tau and Aß-amyloid, both of which are considered to be toxic to neurons. Recent advances have shown small molecule inhibitors of protein aggregation with emphasis on tau, with activities mediated by the direct interference of self-assembly. The inhibitors can be clustered in several compound classes according to their chemical structure, with subsequent description of the structure-activity relationships, showing that hydrophobic interactions are prevailing.

Tau protein inhibitors Emerging Drugs Chapters

This segment of the Tau protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tau protein inhibitors Emerging Drugs

R-phenserine: Annovis BioR-enantiomer (positive isomer) of phenserine, being developed by Annovis Bio (formerly QR Pharma), under a licence from Horizon Therapeutics plc (formerly Horizon Pharma), for the treatment of Alzheimer's disease (AD) and dementia in Down syndrome (AD-DS), Parkinson's disease (PD), stroke and traumatic brain injuries. Currently, it is in phase 2 of development stage for the treatment of Mild cognitive impairment.

Bepranemab: UCBBepranemab (also known as UCB 0107) is a recombinant, humanised, full length IgG4 monoclonal antibody targeting a central tau epitope, being developed by UCB pharma for the treatment of Alzheimer's disease; Progressive supranuclear palsy. Currently, it is in phase 1 stage of development.

Hydromethylthionine mesylate (TRx-0237): TauRx Pharmaceuticals Hydromethylthionine mesylate (TRx 0237) is an orally available, second-generation inhibitor of tau protein aggregation and TDP-43 aggregation being developed by TauRx Pharmaceuticals and is currently in phase 3 stage of development for the treatment of Alzheimer's disease and Dementia.

Tau protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Tau protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Tau protein inhibitors

There are approx. 15+ key companies which are developing the Tau protein inhibitors. The companies which have their Tau protein inhibitors drug candidates in the most advanced stage, i.e. phase III include, TauRx Pharmaceuticals.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Tau protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tau protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tau protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tau protein inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Tau protein inhibitors R&D. The therapies under development are focused on novel approaches for Tau protein inhibitors.

Tau protein inhibitors Report Insights

• Tau protein inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Tau protein inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Tau protein inhibitors drugs?
• How many Tau protein inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Tau protein inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Tau protein inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Tau protein inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Annovis Bio
• UCB Biopharma
• TauRx Pharmaceuticals
• Voyager Therapeutics
• Oligomerix
• APRINOIA Therapeutics
• Sangamo Therapeutics
• AC Immune
• Eli Lilly and Company
• Denali Therapeutics Inc
• Takeda
• TAU BIO-LOGIC
• VITRUVIAN BioMedical
• BeyondBio
• DTx Pharma
• Eisai Co Ltd
• reMYND
• Dong-A ST

Key Products

• R-phenserine
• Bepranemab
• Hydromethylthionine mesylate (TRx-0237)
• Vectorized tau antibodies
• ST 501
• ACI 3024
• AT 8 antibody
• ATV:BACE1/Tau
• TBL 100
• YM 7555
• BEY-2153
• MSUT2 programme
• E 2814
• ReS19 T
• NB 02